News | May 15, 2013

New Data Validates Importance of Contact Force Sensing to Improve Catheter Ablation

Endosense, tacticath, contact force, electrophysiology

May 13, 2013 – New study data released at the Heart Rhythm Society (HRS) meeting last week validates the importance of contact force technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias. Unveiled in HRS abstracts, the data also demonstrated the ability of the Endosense TactiCath ablation catheter to detect excessive contact force during robotic catheter navigation.

A key Endosense abstract at the society’s 34th annual HRS congress was presented by Moussa Mansour, M.D., director of the cardiac electrophysiology laboratory as well as the atrial fibrillation program at Massachusetts General Hospital. His abstract, “Application of Contact Force Guidelines Increases Durable Isolation after Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation,” provided evidence of the value of combining three contact force parameters to improve durability of pulmonary vein isolation (PVI) to treat paroxysmal atrial fibrillation (PAF). These include Endosense’s contact force (CF); Force Time Integral (FTI); and lesion index (LSI). Featured in Endosense’s new TactiCath Quartz device, LSI is a sophisticated algorithm that combines radiofrequency power, ablation time and contact force applied to the cardiac tissue in order to estimate lesion formation in real time.

Contact force guidelines were developed from Endosense’s TOCCATA study, a 12-month study completed in 2010, which found that clinical outcomes improve with CF > 20 g; and its later EFFICAS I post-market clinical trial, which not only revealed the value of FTI, but established the clinical practice guideline of an absolute minimum FTI of 400 gs per individual ablation lesion. Early results of the TOCCASTAR investigational devices exemption (IDE) study presented by Mansour underscored this guidance and showed that, in a subgroup that underwent a redo procedure, subjects treated with the combined CF guidelines of CF > 20 g, FTI > 400 gs and LSI > 5 showed the strongest improvement in pulmonary vein isolation rate: 80 percent when all criteria were fulfilled versus 46 percent when not all criteria were fulfilled.

“The data has clearly demonstrated the importance of contact force in achieving durable pulmonary vein isolation following the catheter ablation treatment of PAF,” said Dipen Shah, M.D., professor of cardiology at the University Hospital Geneva and co-author of the paper. “I believe these new CF guidelines have great potential to improve clinical practice and, ultimately, lead to better patient outcomes.”

Endosense CEO Jan Keltjens added, “Endosense has made significant strides since demonstrating the correlation between contact force and the durability of PVI for the treatment of PAF. In addition to establishing contact force guidelines, we have found that the long-term success of PVI is greatest when minimum CF is combined with minimum FTI and LSI parameters.”

In the abstract “Quantitative Magnetic Resonance Imaging Analysis of the Relationship between Contact Force and Left Atrial Scar Formation after Catheter Ablation of Atrial Fibrillation,” Dr. Christian Sohns of Kings College London examined the relationship between contact force achieved during catheter ablation for PAF and late gadolinium enhancement MRI (LGE-MRI) signal intensity as a measure for durable isolation following PVI. He found that increased LGE-MRI signal intensity correlates with increased FTI values, hence an important guidance for long-term isolation.

While low contact force can lead to ineffective lesions, excessive contact force may cause safety concerns. In the third Heart Rhythm 2013 abstract, “Complementary Techniques and Location of Excessive Contact Force Detection in the Left Atrium with Robotic Catheter Navigation,” Sarah K. Hussain, M.D., of the University of Virginia, Charlottesville, concluded that in a simulated bench experiment, Endosense’s TactiCath ablation catheter could enhance the capabilities of current robotic catheter systems in detecting excessive contact force wherever it occurs in the left atrium.

For more information: www.endosense.com

 

Related Content

Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

LAA closure during open heart surgery in the LAACS Study showed better outcomes for all patients.

Feature | Left Atrial Appendage (LAA) Occluders| September 07, 2017
September 7, 2017 — Closure of the left atrial appendage (LAA) during heart surgery protects the brain, according to
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices

Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices.

Feature | EP Lab| August 29, 2017 | Dave Fornell
August 29, 2017 — The U.S.
Real-World Analysis Compares Safety, Effectiveness of Apixaban Versus Warfarin
News | Antiplatelet and Anticoagulation Therapies| August 28, 2017
August 28, 2017 — Bristol-Myers Squibb Company and Pfizer Inc.
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Overlay Init